SCHEMBL18591875

SCHEMBL18591875

CC(C)c1ccc(N2CCN(C(=O)CCOCC(=O)O)CC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 9/20 0.49
▸ SMN1; SMN2 Q16637 4/20 0.49
▸ GAA P10253 3/20 0.49
▸ NPC1 O15118 3/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ LMNA P02545 2/20 0.49
▸ MAPK1 P28482 2/20 0.49
▸ ALOX15 P16050 1/20 0.49
▸ TSHR P16473 1/20 0.49
▸ ALOX12 P18054 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ NPSR1 Q6W5P4 1/20 0.47
▸ ALDH1A1 P00352 3/20 0.46
▸ FKBP1A P62942 2/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ PANK3 Q9H999 2/20 0.46
▸ GRM5 P41594 2/20 0.46
▸ MEN1 O00255 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18591878 0.84 GRM5 (0.53) MAPTSMN1; SMN2GAANPC1KDM4E
SCHEMBL18530398 0.82 MAPT (0.41) MAPTSMN1; SMN2GAANPC1KDM4E
SCHEMBL18530448 0.82 MAPT (0.41) MAPTSMN1; SMN2GAANPC1KDM4E
SCHEMBL23544874 0.79 MAPT (0.64) MAPTSMN1; SMN2GAAKDM4ELMNA
SCHEMBL14923989 0.77 AKR1C3 (0.64) MAPTSMN1; SMN2GAAKDM4ELMNA
SCHEMBL25839454 0.77 FKBP1A (0.53) MAPTSMN1; SMN2GAANPC1KDM4E
SCHEMBL23544870 0.76 KDM4E (0.56) MAPTSMN1; SMN2GAAKDM4ELMNA
SCHEMBL23544893 0.76 MAPT (0.54) MAPTSMN1; SMN2GAANPC1KDM4E
SCHEMBL10288811 0.75 PANK3 (0.58) MAPTSMN1; SMN2GAAKDM4ELMNA
SCHEMBL23544887 0.75 MAPT (0.48) MAPTSMN1; SMN2GAAKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230263893-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS ARVINAS OPERATIONS, INC. 2023-08-24 — — US disclosed
US-20170065719-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS ARVINAS OPERATIONS, INC. 2017-03-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230263893-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS BRPF3, STUB1, BRDT MAPT 2849/4885SMN1; SMN2 4324/4885GAA 1277/4885
US-20170065719-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS BRPF3, STUB1, BRDT MAPT 2849/4885SMN1; SMN2 4324/4885GAA 1277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback